S
Sonia M. Davis
Researcher at University of North Carolina at Chapel Hill
Publications - 80
Citations - 19288
Sonia M. Davis is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Antipsychotic & Risperidone. The author has an hindex of 49, co-authored 80 publications receiving 18120 citations. Previous affiliations of Sonia M. Davis include North Carolina Department of Health and Human Services & Harvard University.
Papers
More filters
Journal ArticleDOI
Gender differences in treatment response to sertraline versus imipramine in chronic depression.
Susan G. Kornstein,Alan F. Schatzberg,Michael E. Thase,Kimberly A. Yonkers,James P. McCullough,Gabor I. Keitner,Alan J. Gelenberg,Sonia M. Davis,Wilma Harrison,Martin B. Keller +9 more
TL;DR: Comparison of treatment response rates by menopausal status showed that premenopausal women responded significantly better to sertraline than to imipramine and that post menopausal women had similar rates of response to the two medications.
Journal ArticleDOI
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
Henry A. Nasrallah,Jonathan M. Meyer,Donald C. Goff,Joseph P. McEvoy,Sonia M. Davis,T. Scott Stroup,Jeffrey A. Lieberman +6 more
TL;DR: The data indicate the high likelihood that metabolic disorders are untreated in patients with schizophrenia, with particularly high rates of non-treatment for hypertension and dyslipidemia.
Journal ArticleDOI
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.
A. John Rush,Lauren B. Marangell,Harold A. Sackeim,Mark S. George,Mark S. George,Stephen K. Brannan,Sonia M. Davis,Robert H Howland,Mitchel A. Kling,Barry R. Rittberg,William J. Burke,Mark Hyman Rapaport,John Zajecka,Andrew A. Nierenberg,Mustafa M. Husain,David Ginsberg,Robert G. Cooke +16 more
TL;DR: This study did not yield definitive evidence of short-term efficacy for adjunctive VNS in treatment-resistant depression.
Journal ArticleDOI
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
Donald C. Goff,Lisa M. Sullivan,Joseph P. McEvoy,Jonathan M. Meyer,Henry A. Nasrallah,Gail L. Daumit,Steven J. Lamberti,Ralph B. D'Agostino,T. S. Stroup,Sonia M. Davis,Jeffrey A. Lieberman +10 more
TL;DR: These results are consistent with recent evidence of increased cardiac mortality in schizophrenia patients and the impact of cigarette smoking is clear, while the relative contributions to cardiac risk of specific antipsychotic agents, diet, exercise, and quality of medical care remain to be clarified.
Journal ArticleDOI
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Richard S.E. Keefe,Robert M. Bilder,Philip D. Harvey,Sonia M. Davis,Barton W. Palmer,James M. Gold,Herbert Y. Meltzer,Michael F. Green,Del D. Miller,José M. Cañive,Lawrence Adler,Theo C. Manschreck,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Trina M. Walker,T. Scott Stroup,Joseph P. McEvoy,Jeffrey A. Lieberman +18 more
TL;DR: Multiple analyses suggested that a broad cognitive deficit characterizes this sample of patients with chronic schizophrenia, which is modestly related to negative symptoms and essentially independent of positive symptom severity.